At Polpharma Biologics, our commitment to excellence begins at the top. With decades of combined experience in the development, manufacture and commercialization of biopharmaceuticals, our international management team brings both knowledge and passion to every project.
Hannes Teissl is a seasoned biopharmaceutical executive with a track record in general management, business turnaround, finance, business development and M&A. Hannes is a Supervisory Board Member of Polpharma Biologics S.A., a company which he was instrumental in establishing over the last 7 years. Prior to joining Polpharma Biologics, Hannes served 22 years at Sandoz, where he held various international management positions, such as Member of the Global Executive Committee, Global Head of M&A, CEO of Sandoz Germany, Global Head of Biopharmaceuticals, Global Commercial Head of API & Out-Licensing for an Anti-infectives and CEO of Sandoz Germany. Hannes holds a Master of Economics from the University of Innsbruck.
Dr. Joerg Windisch
President of the Management Board
Dr. Joerg Windisch has around 25 years of experience in the development, manufacture and regulatory licensure of biologic therapies. Since joining Polpharma Biologics, Dr. Windisch has made significant contributions to the organization’s formation and growth, and the development of its frontrunner products. Prior to joining Polpharma, Dr. Windisch served as the Chief Operating Officer (COO) for Affimed, a NASDAQ-traded biotech company which develops innovative bi- and trispecific antibodies as immune cell engagers to treat various kinds of cancer. Before that, Dr. Windisch spent almost 20 years at Novartis/Sandoz where he most recently served as Chief Scientific Officer (CSO) for Sandoz Biopharmaceuticals. He was a key figure in developing the first biosimilars approved in Europe and the US.
Member of the Management Board
Jan Krzewinski is a Management Board Member and CFO of Polpharma Biologics. Prior to his current position Jan held various roles at Polpharma including the Director of the Chariman’s Strategic Projects Office. Before joining Polpharma he spent almost 9 years working for Mid Europa Partners, the largest CEE-focused private equity fund where he was responsible for executing and monitoring investments. While at Mid Europa Partners Jan held supervisory board-level positions at Lux Med, Diagnostyka, Alpha Medical and Polskie Koleje Linowe. Jan continues to serve on the supervisory boards of Herbapol Lublin and the EFC Educational Foundation. Jan is a graduate of the London School of Economics and Political Science (BSc) and Johns Hopkins University, SAIS (MA).
Dr. Piotr Zień
Director Research & Development CMC
Piotr Zien is an experienced R&D professional skilled in biopharmaceutical drugs development. As a Research and Development Director for Polpharma Biologics, Piotr manages the organization’s biopharmaceutical laboratory in Gdańsk, with responsibility for the in-house development of biosimilar molecules. Piotr has more than 15 years of experience in the biotech sector, during which he was the leader of the development projects both for innovative and biosimilar molecules. Piotr graduated from UMCS in Lublin with an MSc in the faculty of biotechnology and with a Ph.D. in molecular biology from the Catholic University of Lublin. He participated in a postdoctoral fellowship in the department of biochemistry at the University of Western Ontario and is a member of the program board in the leading Polish university in Gdańsk.
Dr. Adriana Kiędzierska-Mencfeld
Technical Operations Director
Dr. Kiedzierska-Mencfeld has more than 10 years of experience in recombinant protein purification and expression in both prokaryotic and eukaryotic systems, and six years of experience in the development and GMP production of biosimilars. Prior to joining Polpharma Biologics as Production Director, Dr. Kiedzierska-Mencfeld spent four years as Head of GMP Production at the biotechnology firm Mabion S.A. She earned her Ph.D. in biochemistry from the Institute of Biochemistry and Molecular Biology at the University of Wroclaw, her MS in molecular biotechnology and biocatalysis from the Technical University of Wroclaw, and completed her master’s thesis at the Technical University of Dresden.
Renate Sporrer is a seasoned biotechnologist with a strong background in biopharmaceutical manufacturing of drug substance and drug product, including the QP release of both sterile and non-sterile finished drug product. She spent nearly 10 years at Sandoz GmbH where she held various leadership positions, including Global Head of QA DP Production, Head of the Cell Culture Production Plant, and Quality Manager of Biopharmaceuticals. Prior to joining Sandoz in 2006, Renate was Consultant, Technical Engineer and GMP Specialist for Chemgineering Planung GmbH. She started her career as a QC lab technician at Boehringer Ingelheim. Renate earned her master’s degree from the University for Applied Sciences: International Business and Engineering in Vienna, Austria.
Dr. Klemen Spaninger
Project Management Director
Dr. Klemen Spaninger is a global pharmaceutical project management expert with extensive experience in biologics. As Director of Project Management for Polpharma Biologics, Dr. Spaninger leverages his strong leadership and entrepreneurial skills to manage processes across the organization’s portfolio of products and services. Prior to joining Polpharma, Dr. Spaninger held roles of increasing responsibility at Sandoz, including Global Program Manager for Biosimilars, Head of Analytical Laboratories DP Biosimilars, and Technical Project Leader for Biosimilars. Earlier in his career, he co-founded DiaGenomi, a startup focused on the development of solutions in various areas of molecular biology. Dr. Spaninger has an MBA from ESSEC business school and a Mannheim business school, Ph.D. in molecular biology from the University of Ljubljana and is a research fellow at Harvard Medical School.
Dr. Guenter Stempfer
Contract Development & Manufacturing Organization Director
Dr. Guenter Stempfer has more than 25 years of experience in the development and manufacture of biosimilars and biologic drugs, most recently serving as Project Director at Novartis before joining Polpharma in 2016. Dr. Stempfer spent the majority of his career at Sandoz GmbH, where he held several roles of increased responsibility, including Head of the Medical Device Unit; Site Head of Biopharmaceuticals; Head of Manufacturing for Biopharmaceuticals; and Plant Manager for various manufacturing facilities. From 2009 to 2013, he was a member of the organization’s local management board. Earlier in his career, Dr. Stempfer managed the process development laboratory for biosimilars at Sandoz’s Austria site in Kundl and, before that, a research and development laboratory in Schaftenau, Austria. He holds an M.S. in biology and a Ph.D. in biochemistry.
BD & Alliances Director,
Administration Director Gdańsk
Tomasz Góralczyk has more than 17 years of experience in pharmaceutical business development, including both licensing-in and licensing-out. Tomasz started at Polpharma as New Product Acquisition Manager, identifying and initiating opportunities to expand the organization’s portfolio of products. He then led the formation of Polpharma’s out-licensing department and strategy as Licensing-Out Director, where he was responsible for licensing out products developed by the Polpharma group of companies. Prior to his time at Polpharma, Tomasz was Head of the Foreign Projects Department at Adamed. He has an MSc in molecular biology from Jagiellonian University in Kraków.
Małgorzata Delke has more than 17 years of professional experience across the pharmaceutical, electronics and banking industries, combining in-depth knowledge of human resources with management experience in production and supply chain functions. Since joining Polpharma as Senior Production Planner in 2002, Małgorzata has held roles of increasing responsibility at the organization, including Production Scheduling Manager and, subsequently, HR Development Manager & HR Business Partner, both for Polpharma Pharmaceutical Works. She earned her MS in Information Science from Adam Mickiewicz University in Poznań, and completed her post-graduate studies for HR managers at Gdańsk University of Technology.
Andrzej Uzdrowski has more than 13 years of professional experience in finance and is currently responsible for operational and strategic controlling at Polpharma Biologics. Prior to joining Polpharma Biologics, he worked in the generics division of Polpharma Group as Head of R&D and B2B Controlling for 11 years, during which time he successfully implemented a number of solutions that increased the quality of the organization’s financial reporting. Andrzej received his master’s degree in international finance and banking from Gdańsk University and completed his post-graduate studies in accounting and controlling at BSB University.
Dr. Louis Boon
Chief Scientific Officer, Bioceros
Dr. Louis Boon is Chief Scientific Officer and Managing Director for Bioceros, a division of Polpharma Group. He is experienced in molecular and cellular immunology and therapeutic antibody development, and has been involved in the trajectory of preclinical preparation and design of first-into-man studies using therapeutic antibodies. A founder of Bioceros BV, Dr. Boon has held various scientific management roles throughout his career, including CSO for 4AZA Bioscience NV and Director of Preclinical R&D for MacroZyme BV. After completing his post-doctoral studies, Dr. Boon helped to found PanGenetics, where he would later hold the position of VP Preclinical (ad interim) following the company’s merger with Tanox Inc. He received his Ph.D. in biochemistry from the University of Amsterdam and completed his post-doctoral work at the University of Amsterdam’s Department of Anatomy and Embryology and Department of Clinical Epidemiology.
Dr. Abraham Bout
Dr. Bram Bout is Chief Executive Officer and Managing Director of Bioceros, a division of Polpharma Group. Earlier, he was Chief Technology Officer at Profibrix BV. Prior to joining Bioceros, Dr. Bout held several management positions with increasing responsibility at Crucell, including Vice President, Protein Production. Dr. Bout is co-inventor of the human PER.C6 production platform, which is used for the development and manufacture of vaccines, monoclonal antibodies, therapeutic proteins and gene therapy products. He studied chemistry at the University of Amsterdam and wrote his Ph.D. thesis on peroxisomal storage disorders. Dr. Bout has published over 50 scientific articles and is co-inventor on 90 patents for the PER.C6 cell line technology and the field of recombinant protein production and gene therapy.
Mission and Vision
We aim to develop high-quality biologic medicines to treat a wide range of conditions and to make these therapies accessible to those who need them.
We adhere to a set of guiding principles meant to foster a positive, enriching atmosphere for our staff and deliver value to all of our stakeholders.